The data is not yet there to proceed to prescribing,” Michael S. Okun, MD, national medical advisor for the Parkinson’s Foundation, told NeurologyLive®. “More importantly, the weight loss associated with GLP-1’s is not desirable in the majority of cases of Parkinson disease and the nausea and vomiting will not be a welcome symptom. The drug and trial is a step in the right direction, though there is much work to do.”
Top Clinical Takeaways
- Lixisenatide demonstrated potential in slowing Parkinson disease progression over a year but raised concerns because of gastrointestinal adverse effects.
- Researchers emphasize the need for longer and larger trials to fully understand the effects and safety profile of lixisenatide in patients with Parkinson disease.
- While the trial results offer promise, longer exposure and evaluation in different stages of Parkinson disease are necessary to ascertain the drug’s efficacy and safety comprehensively.